( MENAFN - PR Newswire) VICTORIA, BC, May 21, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX ), a clinical-stage biotechnology company leveraging its proprietary DiffuSphereTM technology to optimize drug delivery for applications with significant unmet need, today announced additional positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis ("EoE"). "New data from the RESOLVE trial's first and second cohorts showed good tolerability and extended signals of potential efficacy out to 24 weeks without meaningful side effects," said Dr.
James Helliwell, Chief Executive Officer of Eupraxia. "We're also seeing data from the third cohort of the trial that suggests improvements in patient-reported symptoms and histological outcomes at 12 weeks. Overall, we are seeing a growing volume of positive data, while maintaining a solid safety margin.
" The Company intends to continue to periodically disclose additional data from the trial. New Clinical Data from the First and Second Cohorts of the RESOLVE Trial The results announced today from the first and second cohorts of the RESOLVE trial, using Eupraxia's DiffuSphereTM technology for EoE, are derived from lower doses of four to eight 1 mg injections of EP-104GI administered to a portion of each patient's lower esophagus. The data show: Clinical Data from the Third Cohort of the RE.